liposomal amphotericin B (AmBisome®)
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fungal Infection
Conditions
Fungal Infection
Trial Timeline
Nov 1, 2006 → Sep 1, 2007
NCT ID
NCT00386997About liposomal amphotericin B (AmBisome®)
liposomal amphotericin B (AmBisome®) is a approved stage product being developed by Gilead Sciences for Fungal Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT00386997. Target conditions include Fungal Infection.
What happened to similar drugs?
8 of 20 similar drugs in Fungal Infection were approved
Approved (8) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00386997 | Approved | Terminated |
Competing Products
20 competing products in Fungal Infection